UNIVERSITY OF CALIFORNIA SAN DIEGO

A first-of-its-kind fluorescent drug called bevonescein successfully highlighted nerve tissue during surgery in a Phase 1-2 trial involving 27 cancer patients undergoing head and neck procedures.

Clinical review pharmacists at The US Oncology Network identified 1,271 cost-saving interventions across 5,600 patients, with 1,180 accepted interventions generating nearly $9 million in total cost of care reductions.

Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.

• Real-world data presented at AUA 2025 shows the CVAC System achieves significant kidney stone volume reduction of up to 99% in most patients, with one study reporting a median clearance rate of 96.4%. • The CVAC System demonstrated superior performance compared to flexible and navigable ureteric access sheath (FANS), removing significantly more absolute stone volume while maintaining consistently low intrarenal pressure. • Multiple studies using Quantitative Stone Analysis Software (QSAS) validate stone volume as a more precise and clinically meaningful measure for assessing kidney stone treatment outcomes.

Immorta Bio's SenoVax, a first-in-class senolytic immunotherapy, demonstrated regression of brain, lung, skin, pancreas, and breast cancers in animal models by targeting senescent cells that protect tumors from immune attack.

Researchers have identified a promising combination therapy using FAK inhibitors with RAF-MEK clamps that effectively overcomes treatment resistance in BRAF V600E-mutated melanoma.

Phase 4 PASSAGE study demonstrates tezepelumab reduced annualized asthma exacerbation rates by 79% in real-world patients with severe asthma after 6 months of treatment.

University of California, San Diego has received IRB approval to conduct independent clinical trials of Nexalin's HALO Clarity device for treating mild traumatic brain injury and PTSD.

Lexicon Pharmaceuticals will host a virtual webcast on January 28, 2025, featuring an in-depth discussion of LX9211, their investigational non-opioid treatment for diabetic peripheral neuropathic pain.

The Immune Profile Score (IPS) test demonstrates potential in determining optimal treatment strategies for NSCLC patients with PD-L1 expression above 50%, helping clinicians choose between immunotherapy monotherapy or combination with chemotherapy.